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Abstract:  
 
Background - Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac disease 
characterized by fibro-fatty replacement of the right and/or left ventricle, often causing 
ventricular dysfunction and life-threatening arrhythmias. Variants in desmosomal genes account 
for up to 60% of cases. Our objective was to establish the prevalence and clinical features of 
ACM stemming from pathogenic variants, in the non-desmosomal cadherin 2 (CDH2), a novel 
genetic substrate of ACM.  
Methods - A cohort of 500 unrelated patients with a definite diagnosis of ACM and no disease-
causing variants in the main ACM genes was assembled. Genetic screening of CDH2 was 
performed through next-generation or Sanger sequencing. Whenever possible, cascade screening 
was initiated in the families of CDH2-positive probands, and clinical evaluation was assessed.  
Results - Genetic screening of CDH2 led to the identification of 7 rare variants: five, identified 
in 6 probands, were classified as pathogenic or likely pathogenic. The previously established 
p.D407N pathogenic variant was detected in 2 additional probands. Probands and family 
members with pathogenic/likely pathogenic variants in CDH2 were clinically evaluated, and 
along with previously published cases, altogether contributed to the identification of gene-
specific features (13 cases from this cohort and 11 previously published, for a total of 9 probands 
and 15 family members). Ventricular arrhythmic events occurred in most CDH2-positive 
subjects (20/24, 83%), while the occurrence of heart failure was rare (2/24, 8.3%). Among 
probands, sustained ventricular tachycardia and/or sudden cardiac death occurred in 5/9 (56%).  
Conclusions - In this worldwide cohort of previously genotype-negative ACM patients, the 
prevalence of probands with CDH2 pathogenic/likely pathogenic variants was 1.2% (6/500). Our 
data show that this cohort of CDH2-ACM patients has a high incidence of ventricular 
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Nonstandard Abbreviations and Acronyms 
ARVC: arrhyhtmogenic right ventricular cardiomyopathy 
SCD: sudden cardiac death 
RV: right ventricle 
LV: left ventricle 
ACM: arrhythmogenic cardiomyopathy 
MAF: minor allele frequency 
VUS: variant of unknown significance 
PVC: premature ventricular complexes 
EC: ectodomain 
VT: ventricular tachycardia 
NSVT: non sustained ventricular tachycardia 
ICD: internal cardioverter defibrillator 
DCM: dilated cardiomyopathy 
ACMG: American College of Medical Genetics and Genomics 
CI: confidence interval 
LoF: loss of function 
EP: electrophysiological study 
CKO: conditional knockout 
ACOG: agenesis of corpus callosum, axon pathfinding, cardiac, ocular, and genital defects 
FM: family member 
WGS: whole-genome sequencing 
WES: whole-exome sequencing 
NGS: next generation sequencing 
SNP: single nucleotide polymorphism 
MI: myocardial infarction 
HF: heart failure 
CVA: cerebrovascular accident 
TW: T wave 
TWI: T wave inversion 
LVEF: left ventricular ejection fraction 
RVEF: right ventricular ejection fraction 
LBBB: left bundle-branch block 





Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiac disease 
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instability predisposing to ventricular arrhythmias and sudden cardiac death (SCD).1,2 The major 
form of the disease (ARVC) is characterized by a predominant right ventricular (RV) 
involvement. However, given the evidence of forms with bi-ventricular or predominant left 
ventricular (LV) involvement,3 the term arrhythmogenic cardiomyopathy (ACM) is now 
preferred.4,5  
ACM is mainly caused by variants in genes encoding proteins of the desmosome (PKP2, 
DSP, DSG2, DSC2, JUP), a specialized junction involved in cell adhesion.5,6 Desmosomes, 
together with the fascia adherens junctions and the gap junctions, are located at the intercalated 
discs, which maintain a tight connection between cardiomyocytes and allow cellular 
communication. In mammals, these 3 functional structures are found in close proximity,7 and 
form a hybrid zone that operates as a single functional network, known as the area composita.8,9 
Nowadays, the idea of ACM being a disease whose functional basis extends beyond the 
desmosome to the wider zone of the intercalated discs, is gaining interest.10,11 In a previous study 
by Mayosi et al, we identified clinically actionable variants in the CDH2 gene, encoding 
cadherin 2, a major structural component of fascia adherens junctions, as a novel genetic 
substrate of ACM.12,13 The concept that the genetic basis of ACM extends to non-desmosomal 
protein components of the intercalated disc, has been further demonstrated by two other studies 
linking the ACM phenotype to variants in the CTNNA3,14 and TJP1 genes.15 
These initial discovery studies12,14,15 highlighted the potential contribution of components 
of the intercalated disc to the pathogenesis of ACM, thus widening its genetic basis. However, 
these findings require validation in large ACM patient cohorts, to allow correct estimates of their 
relative contribution, prevalence, and clinical characteristics. To this end, we have collected the 








This article is published in its accepted form; it has not been copyedited and has not appeared in an issue of the journal. Preparation for 
inclusion in an issue of Circulation: Genomic and Precision Medicine involves copyediting, typesetting, proofreading, and author review, 
which may lead to differences between this accepted version of the manuscript and the final published version. 
i  ti l  i  li  i  it  t  ; it  t  it    t  i   i   t  j l. ti   
i l i  i   i   i l ti  i   i i  i i  i l  iti , t tti , i ,  t  i , 
i   l  t  i  t  t i  t  i   t  i t  t  i l li  i . 
to validate the contribution of CDH2 variants to ACM and to establish a reliable prevalence. As 
a second step, we performed, whenever possible, cascade screening in the families of CDH2 
positive probands. Finally, to identify gene-specific features, we analyzed all CDH2-positive 
probands and affected family members from this and previously published studies,12,13 for a total 
of 9 probands and 15 family members. 
Methods 
All data, analytical methods, and study materials supporting this study are available from the 
corresponding author on reasonable request for purposes of reproducing the results or replicating 
the procedures. The study was approved by the local Ethics institutional Review Boards, and the 




 Most of the 500 patients were Caucasian (n=416; 83%), followed by Han Chinese (n=77; 15%) 
and African-American (n=2). In 5 cases, ethnicity was unknown. Males were 59% and females 
41%.  
Genetic findings in CDH2 
We identified 7 rare genetic variants (MAF<0.0001) in CDH2, 6 missense and 1 frameshift, in 8 
unrelated subjects (Tables 1-2; Figure 1-Panel A). Among these, one variant was classified as 
pathogenic (p.D407N), 4 as likely pathogenic (p.P205L, p.N261D, p.N658Kfs*3, p.P679A), and 
2 as variants of unknown significance (VUS) (Table 1). Cascade family screening was feasible in 
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subjects (7 variant-positive and 5 variant-negative). An additional family member, affected by 
ACM, died suddenly before genetic testing could be performed.  
The p.D407N pathogenic variant, previously identified in 5 affected subjects of 2 
independent studies,12,13 was also detected in 2/500 unrelated subjects comprising this study 
cohort. Both probands satisfied major ACM diagnostic criteria, such as structural dysfunction 
(important dilatation of RV) and depolarization/repolarization abnormalities (Table 2). One of 
the two p.D407N probands, symptomatic for arrhythmic events, had three affected relatives, one 
brother who died suddenly at age 18 years, another brother and a nephew (both carrying the 
p.D407N variant) with RV involvement and frequent premature ventricular complexes (PVCs) 
despite beta-blocker therapy. 
The p.N658Kfs*3 frameshift variant, resulting from a nucleotide duplication that 
putatively results in premature termination of the protein, is the first non-missense variant thus 
far described in CDH2–associated ACM. The patient with this likely pathogenic variant is a 
female, diagnosed at 59 years, with dilatation of the RV, accompanied by 
depolarization/repolarization abnormalities and frequent PVCs (>500 per 24 hours, Table 2).  
The other three variants classified as likely pathogenic (p.P205L, p.N261D and p.P679A) 
are ultra-rare missense variants (0 or 1 allele in gnomAD), located in the extracellular region of 
the protein (Figure 1-Panel A), with evidence in support of pathogenicity coming also from 
genotype-phenotype correlation data in the respective patient families (Figure 2). The p.N261D 
variant affects the Ca2+-binding site in the ectodomain 1-2 (EC1-EC2)-inter-domain that plays a 
key role in cadherin-cadherin adhesion.20 This variant was identified in a proband with sustained 
ventricular tachycardia (VT), implanted with an ICD at age 18 years, in one affected brother with 
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cousin with signs of non-compaction and an episode of heart failure triggered by 
supraventricular tachycardia (Figure 2). The p.P679A positive individual is a female who 
presented with syncope at age 20 years and who eventually developed biventricular structural 
impairment (Table 2). The variant was also present in her affected father, while it was absent in 
her unaffected sibling (Figure 2). The p.P205L variant resides in the EC1 domain that, together 
with EC2, is considered an essential structural element for cadherin-mediated intercellular 
adhesion.21 This variant was identified in a male proband who presented with repolarization 
abnormalities and non-sustained VTs. Cascade family screening also identified the variant in the 
affected father, while it was absent in 3 unaffected family members. A brother, positive for the 
same variant, was only partially investigated, and at present he cannot be clinically classified 
(Table 2; Figure 2). 
Finally, two rare variants were classified as VUSs due to lack of a high degree of 
conservation of the affected residue, few clinical information available and the presence of the 
variant in exome/genome datasets, albeit with MAFs much lower than the disease prevalence 
(Table 1).22 
Pathogenic/likely pathogenic variants in other genes associated with arrhythmogenic 
and/or dilated cardiomyopathy (DCM) were identified in only 3 probands not carrying any 
CDH2 variant (Supplemental Table 1). 
In conclusion, 7 rare variants in CDH2 were identified in 8 out of 500 ACM unrelated 
patients (1.6%; 95% CI 0.5-2.7%) who lack a pathogenic/likely pathogenic variant in the major 
ACM genes. Considering only the 6 patients with ACMG-graded pathogenic/likely pathogenic 
variants, the prevalence of CDH2 clinically actionable variants in this ACM cohort is 1.2% 
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CDH2 genetic variability and variant location 
Since CDH2 is a novel human disease gene and in order to aid the eventual classification of 
genetic variants, it could be useful to evaluate its natural genetic variability. To this end, we took 
advantage of the publicly-available exome/genome datasets including more than 140,000 
subjects.  
CDH2 is a gene extremely intolerant to loss-of-function variation (LoF), as indicated by 
the constraint metrics in the gnomAD database, with a high discrepancy between the number of 
expected (n=41) and observed (n= 6) LoF variants.  
At the same time, the CDH2 gene, as many other genes, seems to be more tolerant to 
missense variation, with 74% of the theoretically expected variants being actually observed in 
the gnomAD population.16 However, the number of subjects with rare (MAF<0.0001) and 
potentially clinically-relevant missense variants differs significantly between the ACM cohort 
(pathogenic/likely pathogenic, 5/500, 1.0%) and the gnomAD population (potentially 
pathogenic, 300/140,000, 0.2%) (p=0.0010). This difference becomes even more striking when 
considering only the ultra-rare (MAF<0.000005) and potentially clinically-relevant missense 
variants, (pathogenic/likely pathogenic, 5/500, 1.0% in ACM cases vs potentially pathogenic, 
59/140,000, 0.04% in gnomAD) (p<0.0001).  
Regarding the localization within the protein of the pathogenic/likely pathogenic amino 
acid substitutions identified in our patient cohort, they exclusively reside in the extracellular 
region of cadherin 2 that appears intolerant to missense variation according to the computational 
analysis by MetaDome (Figure 1-Panel B).19 Specifically, most of these variants cluster in the 
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CDH2-associated ACM clinical features 
To identify gene-specific clinical features, we considered all probands with CDH2 pathogenic 
and likely pathogenic variants of the present (n=6) and of the two previously published studies 
(n=3)12,13 along with their 15 affected family members with complete clinical information (7 
from this and 8 from previously published studies), for a total of 24 patients with CDH2-
associated ACM (Table 3).  
Sustained VTs and SCD occurred in 5/9 probands (56%). All except one of the remaining 
index cases had frequent PVCs and/or non-sustained VTs, with an ICD implanted in 6 (67%) 
(Table 3). The only proband with no spontaneous arrhythmias had VT induction at the EP study 
and recurrent episodes of heart failure. None of the other probands had heart failure episodes and 
none underwent a heart transplant during a mean follow-up period of 13.5±8.5 years. Regarding 
the structural alterations observed, all probands had right ventricular involvement, with a 
biventricular involvement observed in 3 (33%).  
Among the 15 clinically affected CDH2-postive family members, 2 suffered SCD and 10 
had frequent PVCs and/or non-sustained VTs (Table 3). Left ventricular involvement was 
present in 4 genotype-positive family members and in only one of them heart failure was 
reported during supraventricular tachycardia.  
Discussion 
The present report provides the first assessment of the prevalence of CDH2 clinically actionable 
variants in ACM, and establishes its potential clinical features. CDH2 encodes cadherin 2, also 
known as N-cadherin, the main protein component of fascia adherens junctions at the 
intercalated disc. The main novel finding of this study is that pathogenic/likely pathogenic 
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Secondly, the CDH2-p.D407N, found in 9 ACM patients, appears to be the most common 
variant associated with CDH2-mediated ACM.  
In addition, this study shows the presence of two rather specific clinical features for this 
cohort of CDH2-ACM. One is that left ventricular involvement was present in one third of 
patients, with a rare evolution toward heart failure despite adequate follow-up period. The 
second is that the majority of CDH2-positive ACM patients have a ventricular arrhythmic 
phenotype (20/24, 83%), an observation with both prognostic and therapeutic implications.  
Prevalence of CDH2 variants in ACM and clinical implications 
After the initial discovery of CDH2 variants as a novel genetic substrate of ACM,12 a finding 
soon after replicated in another study,13 the need of estimating the contribution of CDH2 variants 
to ACM pathogenesis in a large patient cohort emerged. Therefore, we have collected a cohort of 
500 genetically-negative ACM patients and performed genetic analysis of the CDH2 gene. The 
prevalence of CDH2 clinically actionable variants identified in this cohort is 1.2% (95% CI 0.2-
2.2%), similar to our original estimation in the discovery study.12 The yield of genetic testing in 
ACM is estimated to be close to 60%,23,24 and therefore, a significant number of patients remains 
genetically-elusive. Although the prevalence of CDH2 variants in ACM is low, this finding is not 
without potentially relevant clinical implications.  
Indeed, the thorough clinical evaluation of those patients with CDH2-ACM enabled the 
identification of few gene-specific features. Specifically, some of the pathogenic variants so far 
identified, such as the p.Q229P12 and the original p.D407N,12,13 seem to be associated with a 
severe arrhythmic phenotype, with recurrent sustained ventricular tachycardia and SCD. It seems 
reasonable to postulate that the sudden deaths which occurred in these families have been 
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consistent with the fact that most of probands and affected family members with CDH2 
pathogenic/likely pathogenic variants, had an arrhythmic phenotype (20/24, 83%), while the 
evolution toward heart failure appeared to be rare despite adequate follow-up.  
These observations matter in terms of risk stratification and clinical management. 
Accordingly, CDH2 genetic screening should be considered in patients with a definite diagnosis 
of ACM but without significant variants in major desmosomal genes. The identification of the 
disease-causing variant has clinical consequences for probands and family members alike. Given 
that the disease progression and arrhythmic risk for ACM patients are mostly linked to physical 
activity,1,5 the early identification of family members with subclinical or silent forms is important 
in order to establish preventive strategies that might have a favorable impact on the natural 
history of the disease. 
Another issue to be considered is that, if the concept that the CDH2-associated ACM has 
a predominantly arrhythmogenic profile will be validated - similar to other genetic forms of 
ACM, such as those linked to lamin A (LMNA), filamin C (FLNC) and phospholamban (PLN)4 - 
specific recommendations for ICD implantation might ensue.25 Clearly, all these observations are 
based on a limited number of patients. Further research and wider ascertainment strategies 
should provide more robust data for accurate genetic counseling of patients with CDH2 variants. 
Mechanistic implications of CDH2 variants and electrical impairment in ACM  
At present, the exact mechanism by which CDH2 variants may affect cadherin 2 protein function 
and foster the clinical development of ACM is unknown; however, current knowledge allows 
discussing possible hypotheses.  
The only non-missense CDH2 variant identified in this study, the p.N658Kfs*3, is 
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RNA decay26 without being translated into protein, leading to loss-of-function by 
haploinsufficiency. The haploinsufficiency mechanism has been described previously for 
truncating variants in proteins primarily involved in cell adhesion, such as the desmosomal 
cadherin DSC227 and other components of the desmosome.28,29 Cadherin 2 (or N-cadherin) 
haploinsufficiency, in particular, has been mimicked in vivo in a cardiac-specific mouse model 
(heterozygous CKO) where it decreases connexin 43 plaque size leading to an increased 
susceptibility to ventricular arrhythmias.30 Connexin 43 is the main structural component of gap 
junctions at the intercalated disc, and its reduction results in slow conduction, favoring 
arrhythmias by reentry.31 Furthermore, in these mice, also the expression of the zonula occludens 
1, another protein of the intercalated disc recently implicated in ACM pathogenesis,15 was 
significantly reduced,30 potentially concurring to the destabilization of gap junctions.  
CDH2-encoded cadherin 2 (N-cadherin) is part of a protein cluster at the intercalated disc 
that also includes the cardiac sodium channel Nav1.532 and the ability of these two proteins to 
influence each other has been demonstrated in induced pluripotent stem cell-derived 
cardiomyocytes of an ACM patient,33 suggesting another potential mechanism of 
arrhythmogenesis.  
The majority of pathogenic or likely pathogenic variants identified so far in CDH2 are 
missense variants. A reasonable hypothesis for their mechanism of action could be that since 
they all reside in the extracellular EC domains of the protein (Figure 1), these variants may 
adversely affect normal adhesive function. Such a mechanism was recently demonstrated in vitro 
for CDH2 missense variants associated to the ACOG syndrome, a multisystemic disorder 
characterized by developmental delay and/or intellectual disability, ocular and genital defects 
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in EC4-EC5 showed a defect in cell-cell adhesion, with consequences both on self-binding and 
trans-binding with wild type cadherin 2 proteins.34 Another multisystemic disorder recently 
associated to genetic variants in CDH2 is the Peters anomaly, mainly characterized by corneal 
abnormalities.35 The reason why some CDH2 variants may create these multisystemic disorders 
while others result in a pure ACM phenotype is currently unknown; further studies are needed to 
unravel the functional effect of specific CDH2 variants and the molecular mechanisms leading 
from cadherin 2 dysfunction to different phenotypes.  
Limitations 
One limitation, intrinsic to the nature of collection of data from multiple sources, is the limited 
number of family members that could favor an ascertainment bias towards the more severe end 
of the spectrum of the disease. The family members effectively evaluated (CDH2-variant 
positive, with available clinical data) are only part of all other potential carriers. The evaluation 
of further CDH2-positive patients should reflect more precisely the different phenotypic 
variability present in this disease subtype, and may modulate the severity of disease or the 
specific clinical features emerged so far.   
This implies that the severity of CDH2 variants, as well as their association with other 
cardiac phenotypes beyond ACM, may need to be refined once a greater number of positive 
patients will be available. 
Conclusions 
The contribution of CDH2 clinically actionable variants to ACM is small but significant. Indeed, 
this rare genetic form appears to be associated in our cohort with a high arrhythmogenic profile 
and, therefore, its evaluation may be reasonable in patients affected by ACM in whom a disease-
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variants in this gene should modify the management of an otherwise still asymptomatic patient, 
as already happens for other rare genetic subtypes, such as LMNA and FLNC, remains to be 
determined. 
We recognize the inherent ascertainment biases present in this type of study; however 
current data suggest that there is a high incidence of ventricular arrhythmias in CDH2-ACM 
patients, with few evolving to heart failure. 
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N. of positive 
FMs 
chr18:25589769 5 c.614C>T p.P205L High Cadherin 1 (EC1) 0.000003984/1 Likely pathogenic 1 2 
chr18:25585879 6 c.781A>G p.N261D Full Cadherin1-2 (EC1-EC2) interdomain - 
Likely 
pathogenic 1 2 
chr18:25572744 9 c.1219G>A p.D407N Full Cadherin 3 (EC3) - Pathogenic 2 2 
chr18:25565494 12 c.1973dupA p.N658Kfs*3 NA Cadherin 5 (EC5) - Likely pathogenic 1 NA 
chr18:25565138 13 c.2035C>G p.P679A Full Cadherin 5 (EC5) 0.000003983/1 Likely pathogenic 1 1 
chr18:25565036 13 c.2137G>C p.D713H Medium Cadherin 5 (EC5) 0.00006365/16 VUS 1 NA 




0.00003982/10 VUS 1 NA 
Genomic coordinates are reported according to the GRCh37/hg19 assembly. Mutation nomenclature has been assigned according to the main transcript of the 
CDH2 gene (NM_001792.4). Conservation has been assessed using the Vertebrate Multiz Alignment & Conservation (100 Species) feature track of the UCSC 
genome browser (https://genome.ucsc.edu): Full- 100% conserved; High- at least 95% conserved; Medium- at least 70% conserved. NA=not applicable. EC= 
extracellular cadherin ectodomain. Minor allele frequencies (MAF)/allele counts are reported considering the total population of the gnomAD database.16 – 
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Arrhythmias Family history 
    
Major Minor Major Minor Major Minor Major Minor Major Minor 
Proband 1 
(p.P205L) 








- - - - NSVT and 





17 years M Caucasian Dilatation of RV, 










- - - LBBB sustained VT, 
superior axis 
12,000 PVCs   
Proband 3 
(p.D407N) 
26 years M Unknown Important 
dilatation of RV, 
hypokinetic. 












Sustained VT, HR= 
210 bpm, LBBB 
pattern, axis = 0° 
- SCD at 18 years 






47 years M Caucasian Severe 
impairment of 







- - - - - 
Proband 5 
(p.N658Kfs*3) 








- PVCs >500 per 24 











- - - - 12,688 PVCs on 
Holter.  Presented 
with cardiac 
syncope. ICD 




arrhythmia cL 155 
msec. 





TW= T wave; TWI= T wave inversion; PVC= Premature ventricular complex; LVEF= Left ventricular ejection fraction; RVEF= Right ventricular ejection 
fraction; VT= Ventricular tachycardia; NSVT= Non-sustained ventricular tachycardia; LBBB=left bundle branch block “-” means not present. # Genetic testing  
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Table 3: Arrhythmogenic features of CDH2-related ACM patients so far described 
 
ACM Patient CDH2 Mutation Proband/FM Sustained VT/SCD 
PVCs>500/24 
h/NSVT ICD Outcome Source 
Family 1 (II-3) p.P205L Proband - + (NSVT, PVCs) - Alive (45 years) This study 
Family 1 (I-1) p.P205L FM - Father - + (NSVT, PVCs) - Alive (76 years) This study 
Family 2 (IV-4) p.N261D Proband + (sustained VT) + (PVCs) + Alive with ICD (39 years) This study 
Family 2 (IV-5) p.N261D FM - Brother - + (NSVT, PVCs) - Alive (36 years) This study 
Family 2 (IV-6) p.N261D FM - Cousin - - - Alive (49 years) This study 
Family 3 (II-1) p.D407N Proband + (sustained VT) - + Alive with ICD (50 years) This study 
Family 3 (II-6) p.D407N Brother - + (PVCs) - Alive (47 years) This study 
Family 3 (III-5) p.D407N Nephew - + (PVCs) - Alive (16 years) This study 
Family 3 (II-10) NA FM - Brother + (SCD) NA - SCD at 18 years This study 
Family 4 (II-4) p.D407N Proband - - + Alive with ICD (75 years) This study 
Family 5 (I-2) p.N658Kfs*3 Proband - + (PVCs) - Alive (67 years) This study 
Family 6 (III-1) p.P679A Proband - + (PVCs) + Alive (27 years) This study 
Family 6 (II-2) p.P679A FM - Father - + - Alive (56 years) This study 
Family 7 
(ACM2 III-3) p.Q229P Proband 
+ 
(sustained VT, SCD) - - SCD at 24 years 11 
Family 7 
(ACM2 III-2) NA FM - Brother 
+ 
(sustained VT, SCD) - - SCD at 21 years 11 
Family 7 
(ACM2 III-4) p.Q229P FM - Cousin - + (NSVT, PVCs) - Alive 11 
Family 7 
(ACM2 III-5) p.Q229P FM - Cousin - + (PVCs) - Alive 11 
Family 7 
(ACM2 II-4) p.Q229P FM - Aunt - - - Alive 11 
Family 7 
(ACM2 II-7) p.Q229P FM - Aunt - - - Alive 11 
Family 8 
(ACM11 CM11.2) p.D407N Proband 
+ 
(sustained VT) - + Alive with ICD 11 
Family 9 (III.2) p.D407N Proband + (BCE with appropriate ICD shocks) + (NSVT, PVCs) + Alive (21 years) 12 
Family 9 (III.1) p.D407N FM - Sister - + (NSVT, PVCs) + Alive (23 years) 12 
Family 9 (III.3) p.D407N FM - Brother - + (PVCs) - Alive (19 years) 12 
Family 9 (II.2) p.D407N FM - Mother - + (PVCs) - Alive (54 years) 12 
 
VT= Ventricular tachycardia; NSVT= Non-sustained ventricular tachycardia; SCD= sudden cardiac death; PVC= Premature ventricular complex; BCE=breakthrough cardiac 
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Figure Legends: 
 
Figure 1: Panel A: Schematic representation of cadherin 2 protein belonging to the superfamily 
of Ca2+ cell surface adhesion proteins. The mature protein is formed by 5 extracellular repeats 
(ectodomains EC1-EC5), a single-pass transmembrane region and a cytoplasmic C-terminal 
domain, while the N-terminal propeptide (P), following the signal peptide, is removed by 
proteolysis (Pfam database EMBL-EBI).18 The length/boundaries of each domain are indicated 
with double-headed arrows just below the protein. All ACM-associated CDH2 genetic variants 
so far identified12,13 are depicted above the protein according to their position. Mutation 
nomenclature has been assigned according to the CDH2 main transcript (NM_001792.4), with 
the amino acid change (p.) reported first and the corresponding nucleotide change (c.) in 
brackets. Pathogenic/likely pathogenic variants are shown in bold. Panel B: CDH2 tolerance 
landscape to missense variation, generated by MetaDome software analysis.19 The tolerance 
score is computed by the MetaDome software using the gnomAD population,16 as a missense 
over synonymous variant count ratio, calculated in a sliding window manner, for each position. 
The tolerance color-coded legend is reported on the left. The pathogenic/likely pathogenic 
missense variants identified in the ACM patient cohort all reside in red/orange regions (i.e. the 
most intolerant to missense variation).  
 
Figure 2: Pedigrees of the 6 families segregating the pathogenic/likely pathogenic variants 
identified in CDH2. The proband is indicated by an arrow. Black-filled symbols indicate affected 
subjects with a definite ACM diagnosis, while grey-coloured symbols stand for partially 
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marked up with “N” correspond to subjects with no clinical evidence of disease at latest clinical 
investigation. + indicates mutation-positive subjects; – indicates mutation-negative subjects. MI 
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